The Nuvisan Group, a European CRO focused on early stage drug development for the life science industry, has signed an agreement with Nestlé Skin Health/Galderma to take over parts of the R&D capacities in Sophia-Antipolis, France.

The Galderma R&D site in Sophia-Antipolis, which opened in 2006, is one of the world’s largest research and development center focused on medical and cosmetic solutions for the skin. The new capabilities will strengthen Nuvisan’s core service lines in bioanalysis, clinical trial supplies and pharmaceutical analytics as well as enhancing the portfolio by adding GMP-API synthesis and formulation capability for prescription drugs and cosmetics. Nuvisan intends to start its operations in Sophia Antipolis in October 2018.

Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies. You can obtain detailed information about the use of cookies on our website by clicking on "More information”.